-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MxkOPheAYZKv1qBaOP7OGkOCYpam1lenemnKHR2DIB+PCdM0tiEw3RRiVASgSwRN eeLmV209IIGrcT9H/N4j/A== 0000950157-09-000553.txt : 20090828 0000950157-09-000553.hdr.sgml : 20090828 20090828133916 ACCESSION NUMBER: 0000950157-09-000553 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090828 DATE AS OF CHANGE: 20090828 EFFECTIVENESS DATE: 20090828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVEN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000815838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 592767632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-17254 FILM NUMBER: 091042563 BUSINESS ADDRESS: STREET 1: 11960 SW 144TH ST CITY: MIAMI STATE: FL ZIP: 33186 BUSINESS PHONE: 3052535099 MAIL ADDRESS: STREET 1: 11960 SW 144TH STREET CITY: MIAMI STATE: FL ZIP: 33185 15-12G 1 form15-12g.htm FORM 15 form15-12g.htm
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 15
 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 
 
Commission File Number:         000-17254      
 

Noven Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)



 
11960 S.W. 144th Street
Miami, Florida 33186
Telephone: (305) 253-5099
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
 
 
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)
 
 
 
 
None
 
  
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 
 
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
Rule 12g-4(a)(1)
  
x
Rule 12g-4(a)(2)
  
¨
Rule 12h-3(b)(1)(i)
  
x
Rule 12h-3(b)(1)(ii)
  
¨
Rule 15d-6
  
¨
 
Approximate number of holders of record as of the certification or notice date:      One                                                             
 
Pursuant to the requirements of the Securities Exchange Act of 1934, Noven Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
 
 
Date:
August 28, 2009
  
By:
/s/ Jeff T. Mihm
         
Jeff T. Mihm
         
Vice President, General Counsel and Corporate Secretary
           
 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----